Benjamin Manach is the Chief Executive Officer (CEO) of Exeliom Biosciences, a pioneering biotechnology company based in Paris, France, known for developing microbiome-based immunotherapies. Exeliom is on the forefront of innovation in treating inflammatory bowel diseases, certain cancers, and infectious diseases, utilizing its lead candidate, EXL01, which targets the NOD2 receptors in immunomodulation. Benjamin Manach, with a background in investment banking and biotechnology, co-founded Exeliom Biosciences alongside a renowned scientific team. Under his leadership, the company has made significant strides in the biopharmaceutical industry, earning multiple awards and securing substantial funding for its research and development initiatives.
October 2025: Exeliom Biosciences successfully completed a €2.85 million extension to its Series A round, bringing the total Series A funding to €11.85 million. This investment will enhance the clinical development of EXL01, focusing on cancers, inflammatory, and infectious diseases, notably aiming to transform EXL01 from a microbiome therapy into a precision NOD2-targeting immunomodulator.
July 2023: The company closed a €24 million Series A funding to advance its clinical trials for EXL01, with focus areas in immuno-oncology and infectious diseases. The funding will push forward the trials of their lead candidate in new therapeutic areas.
June 2024: Exeliom Biosciences announced its collaboration with REMIND, a consortium of French gastroenterology departments, focusing on a phase II post-operative interventional trial in Crohn’s disease.
March 2023: The company launched phase II clinical trials of EXL01 in combination with immune checkpoint inhibitors, aiming to innovate in immuno-oncology for various cancers.
| Attribute | Information |
|---|---|
| Full Name | Benjamin Manach |
| Born | Not publicly available |
| Nationality | French |
| Occupation | CEO of Exeliom Biosciences |
| Known For | Biotechnological innovations |
| Net Worth | Not publicly available |
| Education | Master’s in Management (ESSEC Business School), Master’s in Molecular and Cellular Biology (Sorbonne University) |
Benjamin Manach hails from France, where he developed a keen interest in the sciences early on. His academic journey took him to prestigious institutions, starting with Classes Prépas and culminating in advanced studies at renowned universities. He pursued a Master’s in Management at ESSEC Business School, which armed him with critical business acumen. Furthering his academic pursuit in the sciences, he attained a Master’s degree in Molecular and Cellular Biology from Sorbonne University. This combination of business and scientific proficiency laid the groundwork for his venture into biotechnology, culminating in the founding of Exeliom Biosciences.
Manach’s professional trajectory reflects a deep-seated commitment to bridging technological innovation and healthcare solutions. His earlier roles spanned investment banking at UBS and venture capital at Pacific Channel, where he harnessed skills crucial for startup growth and funding. Upon transitioning to the biotechnology sector, he engaged with pharmaceutical regulatory affairs at Amgen and operational roles at Theravectys. These multifaceted experiences provided a solid foundation for co-founding Exeliom Biosciences in 2016, aiming to transform microbiome-based therapeutics.
Exeliom Biosciences, under the leadership of Benjamin Manach, stands as a beacon of innovation in the biotechnology space, specifically microbiome therapy. As of 2025, the company has aggressively pushed the boundaries of biotherapeutics. Its flagship product, EXL01, has reached Phase II clinical trials in several therapeutic areas, notably oncology, inflammatory bowel diseases, and infectious diseases. The company actively collaborates with academic institutions and medical bodies to pioneer treatments that could redefine therapy for multiple ailments. The decision to focus on precision modulation of the immune system underscores Exeliom's forward-thinking approach, potentially shaping future market and clinical trends in biotechnology.
Benjamin Manach remains a pivotal figure in advancing biotechnology through the application of microbiome-based therapies, positioning Exeliom Biosciences as a potent player capable of transformative impacts on global healthcare practices. His guiding philosophy of intertwining robust scientific methodology with strategic business insights continues to propel Exeliom’s innovations. As clinical trials progress and the company expands its therapeutic scope, Manach's leadership could see these biotherapeutics revolutionize disease treatment paradigms, fostering a more precise, patient-centered approach in medicine. His legacy in the biotech field, especially concerning immunotherapy, is anticipated to shape future biotechnology innovations and application landscapes.